$53 M

SAVA Mkt cap, 29-May-2020
Cassava Sciences Net income (Q1, 2020)-1.1 M
Cassava Sciences EBIT (Q1, 2020)-1.2 M
Cassava Sciences Cash, 31-Mar-202025.6 M
Cassava Sciences EV27.5 M

Cassava Sciences Income Statement

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

11.5m10.9m41.1m

Revenue growth, %

(100%)

R&D expense

8.3m7.6m4.9m7.3m9.1m9.2m7.6m3.0m

General and administrative expense

6.7m7.2m4.8m5.1m5.1m5.8m4.3m3.7m3.4m

Operating expense total

15.0m14.8m9.8m12.4m14.2m15.0m11.9m6.7m3.4m

EBIT

(3.5m)(3.9m)31.4m(12.4m)(14.2m)(15.0m)(11.9m)(6.7m)(5.0m)

EBIT margin, %

(31%)(36%)76%

Interest income

901.0k451.0k106.0k47.0k57.0k107.0k38.0k105.0k328.0k

Pre tax profit

(2.6m)31.5m(12.4m)(14.1m)

Income tax expense

(73.0k)(73.0k)(73.0k)

Net Income

(2.6m)(3.4m)31.5m(12.4m)(14.1m)(14.8m)(11.9m)(6.6m)(4.6m)

Cassava Sciences Balance Sheet

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

73.1m49.4m48.6m40.6m31.3m16.6m10.5m19.8m23.1m

Accounts Receivable

236.7m

Prepaid Expenses

358.0k253.0k265.0k239.0k392.0k184.0k233.0k

Inventories

Current Assets

98.5m56.5m50.1m40.8m31.7m19.1m10.7m20.0m23.3m

PP&E

122.0k629.0k65.0k215.0k232.0k156.0k87.0k47.0k

Total Assets

99.0m56.9m50.1m40.9m31.9m19.3m10.8m20.1m23.5m

Accounts Payable

464.0k361.0k445.0k173.0k1.0m303.0k424.0k294.0k453.0k

Short-term debt

90.0k

Current Liabilities

13.3m10.0m1.8m850.0k2.6m665.0k1.1m511.0k1.4m

Long-term debt

90.0k

Total Debt

180.0k

Total Liabilities

54.6m43.7m1.8m850.0k2.6m665.0k1.1m511.0k1.4m

Common Stock

45.0k45.0k45.0k46.0k46.0k7.0k17.0k22.0k

Additional Paid-in Capital

176.4m148.7m152.4m156.5m160.0m164.1m167.1m183.6m190.7m

Retained Earnings

(132.2m)(135.7m)(104.1m)(116.5m)(130.6m)(145.5m)(157.4m)(164.0m)(168.6m)

Total Equity

44.4m13.1m48.3m40.1m29.4m18.6m9.7m19.6m22.1m

Financial Leverage

2.2 x4.3 x1 x1 x1.1 x1 x1.1 x1 x1.1 x

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

62.8m71.7m73.8m88.2m51.6m51.5m49.7m45.9m44.6m42.1m37.2m36.4m34.0m26.6m24.6m21.2m17.3m14.1m11.9m10.7m9.6m20.4m19.1m18.5m17.8m25.6m

Accounts Receivable

908.0k231.0k

Prepaid Expenses

15.0k493.0k475.0k378.0k127.0k3.0k389.0k141.0k482.0k358.0k119.0k200.0k520.0k299.0k115.0k456.0k126.0k12.0k288.0k155.0k91.0k276.0k140.0k49.0k385.0k

Current Assets

102.0m100.1m96.4m92.9m54.5m52.8m51.4m47.2m45.3m43.5m39.4m37.5m35.4m28.4m24.7m22.2m17.4m14.1m12.2m10.9m9.7m20.7m19.3m18.6m18.2m25.9m

PP&E

192.0k157.0k87.0k76.0k72.0k69.0k256.0k242.0k228.0k201.0k187.0k250.0k214.0k190.0k173.0k139.0k122.0k104.0k88.0k75.0k61.0k33.0k

Total Assets

102.6m100.6m96.8m93.3m54.9m53.2m51.8m47.3m45.4m43.6m39.6m37.8m35.7m28.6m24.9m22.5m17.6m14.3m12.4m11.1m9.8m20.8m19.5m18.8m18.4m26.0m

Accounts Payable

604.0k556.0k502.0k507.0k366.0k435.0k531.0k428.0k360.0k822.0k255.0k465.0k898.0k1.0m378.0k1.1m573.0k658.0k712.0k421.0k962.0k549.0k495.0k594.0k340.0k608.0k

Short-term debt

67.0k

Current Liabilities

12.8m13.1m12.9m13.8m9.7m9.2m9.7m1.6m1.7m2.4m1.2m1.8m2.6m3.3m2.0m2.2m883.0k999.0k1.0m758.0k1.3m862.0k902.0k937.0k907.0k1.1m

Long-term debt

68.0k45.0k23.0k

Total Debt

68.0k45.0k23.0k67.0k

Total Liabilities

59.6m57.1m51.5m46.9m41.5m39.0m37.5m1.6m1.7m2.4m1.2m1.8m2.6m3.3m2.0m2.2m883.0k999.0k1.0m758.0k1.3m862.0k970.0k982.0k930.0k1.1m

Common Stock

45.0k45.0k45.0k45.0k45.0k45.0k45.0k45.0k45.0k45.0k46.0k46.0k46.0k46.0k46.0k46.0k46.0k7.0k7.0k7.0k7.0k17.0k17.0k17.0k17.0k25.0k

Additional Paid-in Capital

173.6m175.1m177.3m180.1m149.4m150.5m151.3m153.2m154.4m155.5m157.5m158.3m159.1m161.7m162.4m163.2m164.9m165.7m166.3m169.9m170.6m183.2m183.9m184.2m184.5m194.5m

Retained Earnings

(131.0m)(131.8m)(132.2m)(133.9m)(136.1m)(136.4m)(137.1m)(107.6m)(110.8m)(114.3m)(119.1m)(122.4m)(126.1m)(136.4m)(139.4m)(143.0m)(148.2m)(152.4m)(155.0m)(159.6m)(162.0m)(163.3m)(165.3m)(166.4m)(167.1m)(169.7m)

Total Equity

43.0m43.5m45.3m46.3m13.4m14.2m14.3m45.7m43.7m41.2m38.4m35.9m33.1m25.3m23.0m20.3m16.7m13.3m11.4m10.3m8.5m20.0m18.6m17.8m17.4m24.8m

Financial Leverage

2.4 x2.3 x2.1 x2 x4.1 x3.8 x3.6 x1 x1 x1.1 x1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x1.2 x1 x1.1 x1.1 x1.1 x1 x

Cassava Sciences Cash Flow

Annual

USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.6m)(3.4m)31.5m(12.4m)(14.1m)(14.8m)(11.9m)(6.6m)(4.6m)

Depreciation and Amortization

163.0k122.0k15.0k45.0k58.0k68.0k69.0k58.0k

Accounts Receivable

7.1m

Accounts Payable

(643.0k)(103.0k)84.0k(272.0k)841.0k(711.0k)129.0k(130.0k)159.0k

Cash From Operating Activities

(260.0k)(7.2m)(6.9m)(9.5m)(9.1m)(12.2m)(8.2m)(4.8m)(2.5m)

Purchases of PP&E

(80.0k)(195.0k)(75.0k)(18.0k)

Cash From Investing Activities

59.9m17.6m5.7m1.2m(192.0k)(2.2m)2.1m(18.0k)

Cash From Financing Activities

8.7m(34.2m)524.0k379.0k(46.0k)(284.0k)14.1m5.8m

Net Change in Cash

68.3m(23.8m)(767.0k)(8.0m)(9.3m)(14.7m)(6.1m)9.3m3.3m

Cassava Sciences Ratios

USDY, 2020

EV/EBIT

-22.5 x

EV/CFO

-23 x

Financial Leverage

1 x